Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Zemaira | Alpha1-proteinase inhibitor (Human) | Severe Alpha1-proteinase inhibitor deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Zeldox | Ziprasidone hydrochloride | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
Zelboraf | Vemurafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Zejula | Niraparib | First Line OC | Reimburse with clinical criteria and/or conditions | Complete | ||
Zejula | Niraparib | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Zaxine | Rifaximin | Hepatic encephalopathy | List with criteria/condition | Complete | ||
Zavesca | Miglustat | Gaucher disease | Do not list | Complete | ||
Zaltrap | Aflibercept | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
Yondelis | Trabectedin | Metastatic Liposarcoma or Leiomyosarcoma | Do not reimburse | Complete | ||
Yescarta | axicabtagene ciloleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete |